While hundreds of studies and trials were conducted at Baylor Hamilton Heart and Vascular Hospital in fiscal year 2016, Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP, FNKF, FNLA, FCRSA, chief of cardiovascular research and education at the Baylor Heart and Vascular Institute for fiscal year 2016, points to five projects initiated as prominent for Baylor Heart and Vascular Institute’ s work:
1. Clinical outcomes and metabolomics and damage associated molecular patterns of AKI in patients undergoing PCI via the radial versus femoral artery approach:
This study demonstrated in thousands of Baylor patients, that heart catheterization through the radial artery was associated with lower complication rates and reduced mortality. The ongoing laboratory portion of the study is prospectively evaluating candidate urine DAMPS and novel urine markers of CI-AKI as well as store research samples of urine for future genetic, genomic, proteomic, and metabolomics research in heart and kidney disease. Primary Investigator: Jeffrey M. Schussler, MD
2. EXTEND-CRS:
A trial to examine the effects of a glucagon-like peptide agonist versus placebo on cardiac fibrosis as measured by MRI and echo imaging, as well as its effects on patients’ Myocardial Injury Summary Score( MISS) and Kidney Injury Summary Score( KISS). The primary inclusion criteria are presence of Type II diabetes mellitus as well as mildly impaired renal function. The study is actively recruiting patients and has had the first few patients complete nine months of treatment with final cardiac MRI and ultrasound tests completed. Primary Investigator: Peter A. McCullough, MD, MPH
3. ACHD-PRO:
This study of patients with heart defects from birth aims to evaluate the internal and test-retest reliability, assess the validity, and define the responsiveness and interpretability of this new ACHD PRO( Adult Congenital Heart Disease Patient-Reported Outcome) tool by exploiting clinical changes in patients’ health status over time. Englishspeaking patients older than 17 years of age with a repaired, treated, or unrepaired CHD qualify for the study. Primary Investigator: Ari Cedars, MD
4. Baylor Hypertrophic Cardiomyopathy Program Development Project:
Hypertrophic cardiomyopathy or abnormal thickness of the heart muscle is the leading cause of death in young athletes. Baylor is testing the most advanced genetic tests and cardiac imaging to detect the process earlier and understand why the heart muscle thickens in some but not in others. Time-resolved, 3D phase contrast magnetic resonance imaging( MRI)( 4D Flow) and Advanced Strain Rate Echocardiography in Patients with Hypertrophic Cardiomyopathy. Hypertrophic cardiomyopathy creates a characteristic blood flow pattern within heart chambers resulting in thickening of ventricular septum and causes a disarray of cardiac muscle fibers using cardiac MRI and echocardiogram with strain rate imaging. Study participants: patients older than 17 years of age with a positive genetic testing for hypertrophic cardiomyopathy, eGFR ≥ 50 ml / min / 1.73m2, and capability to undergo MRI qualify for the study. Primary Investigator: Peter A. McCullough, MD, MPH
5. PROMIS:
This government funded study organized by the Patient Centered Outcomes Research Institute will attempt to develop and evaluate a health assessment to phenotype heart failure patients. Newly diagnosed heart failure patients will complete a questionnaire followed by an optional phone survey. The primary inclusion criteria are presence of heart failure and absence of dementia. Primary Investigator: Peter A. McCullough, MD, MPH
OUTCOMES 2016
65